

Metastatic Synovial Sarcoma: Experience from a Tertiary Care Center from India

Abstract

Background: Synovial sarcoma represents 8% of all soft-tissue sarcoma (STS). It is a high-grade STS, and 50% of patients develop metastasis. The most common site of metastasis is the lungs, lymph nodes followed by bones. Ifosfamide-based chemotherapy is associated with improved outcome. In this study, we report our experience of metastatic synovial sarcoma according to primary sites, metastatic pattern, and their outcome. **Materials and Methods:** This was a retrospective observational study carried out at our institute from January 2013 to December 2016. The aim of our study was to evaluate the pattern of metastasis, response to chemotherapy, and survival in patients with metastatic synovial sarcoma. **Results:** Over a period of 4 years, 43 patients with metastatic synovial sarcoma were diagnosed with median age of 30 years. Nearly 70% of patients had lung metastasis, other site of metastasis were lymph node, bone, and liver. Thirty patients received chemotherapy with a combination of ifosfamide and doxorubicin. The overall response rate was 87% with median progression-free survival of 8 months. Patients with lung only metastasis had better survival compared with nonpulmonary metastatic site (18 months vs. 12 months). The median survival was 18 months. **Conclusion:** Metastatic synovial sarcoma is chemoresponsive tumor with lung being the most common metastatic site. Patients with lung only metastasis had a better outcome than nonpulmonary metastasis.

Keywords: Metastatic synovial sarcoma, sarcoma, synovial sarcoma

Introduction

Synovial sarcoma represents 8%–10% of all soft-tissue sarcoma (STS). Synovial sarcomas may be diagnosed at any age, but the mostly occurs in young adults, between 15 and 35 years of age, and more commonly in males.^[1] Although relatively rare, synovial sarcoma is the third-most common extremity STS. It affects mostly young adults, with a median age of 35 years.^[2] Despite its name, synovial sarcoma is a misnomer; it does not originate from synovial tissue. It may sometimes originate near the joint but never within it. Its cellular origin is undefined.^[3] Sometimes, it may be encountered in regions without apparent relationship to synovial structures, including the head and neck (<10%), thoracic and abdominal wall (<10%), or intrathoracic sites.^[4] Synovial sarcomas are of four subtypes – monophasic fibrous (spindle), monophasic epithelial, biphasic, and poorly differentiated and monophasic subtype being the most common.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

Biphasic subtype has both, epithelial and spindle cell components.^[5] Its unique t(X: 18)(p11.2; q11.2) translocation helps to define the diagnosis and to distinguishes this subtype from other STSs.^[6]

Synovial sarcoma is an aggressive STS with a higher propensity for recurrence and metastasis. Overall 50% of patients develop metastatic disease either at initial presentation or later in the disease course. The most common site of metastasis is the lungs (74%–81%), lymph nodes (3%–23%), and bones (10%–20%).^[7-9] In this study, we report our experience of metastatic synovial sarcoma according to primary sites, metastatic pattern, and their outcome.

Material and Methods

Study

This was a retrospective descriptive study carried out at Kidwai Cancer Institute, a tertiary care center at Bengaluru, India.

Patient eligibility

Patients of metastatic synovial sarcoma (either at initial presentation or relapsed)

How to cite this article: Babu KG, Patidar R, Kuntegowdanahalli CL, Dasappa L, Jacob LA, Babu S, et al. Metastatic synovial sarcoma: Experience from a tertiary care center from India. *Indian J Med Paediatr Oncol* 2019;40:S95-8.

**K Govind Babu,
Rajesh Patidar,
C Lakshmaiah
Kuntegowdanahalli,
Lokanatha Dasappa,
Linu Abraham
Jacob,
Suresh Babu,
AH Rudresha,
Lokesh N Kadabur,
LK Rajeev,
Deepak Koppaka,
Vikas Asati**

Department of Medical
Oncology, Kidwai Cancer
Institute, Bengaluru, Karnataka,
India

Address for correspondence:

Dr. Rajesh Patidar,
Room No. 214, PG Mens
Hostel, Kidwai Cancer
Institute, Near NIMHANS,
Bengaluru - 560 029,
Karnataka, India.
E-mail: patidarrajesh122@
gmail.com

Access this article online

Website: www.ijmpo.org

DOI: 10.4103/ijmpo.ijmpo_237_17

Quick Response Code:



evaluated at our institute from January 2012 and December 2016 were included in this study. Biopsy from the primary site or accessible metastatic site was performed. The diagnosis was made by histopathological examination and appropriate immunohistochemistry marker such as cytokeratin, epithelial membrane antigen, desmin, vimentin, smooth muscle antigen, and S-100. All patients underwent staging evaluation with computed tomography (CT) scan/magnetic resonance imaging of primary site and CT scan of thorax and abdomen.

Treatment

Patients with the Eastern Cooperative Oncology Group performance status (PS) of 0–2 received chemotherapy. Combination of ifosfamide (1.8 g/m² days 1–3) and doxorubicin (75 mg/m² day 1) repeated every 21 days was used in all eligible patients. Maximum 6 cycles were planned depending on interim reassessment and tolerability.

Response assessment

Reassessment CT scan was performed at the end of 3 cycles of chemotherapy or on suspected clinical progression. The response evaluation was based on RESIST 1.1 criteria. All patients with stable disease, partial response, or complete response received another 3 cycles of chemotherapy.

Statistical analysis

SPSS software, version 23.0 (SPSS, Chicago, IL, USA) was used for all statistical analysis. The association of different variables was analyzed using the log-rank test. Multivariate analysis was done to test the correlation of different factors with survival. Overall survival analysis was done using the Kaplan–Meier method.

Results

Over a period of 4 years, 43 patients with metastatic synovial sarcoma were diagnosed at our institute.

The median age at diagnosis was 30 years (10–70 years). A female preponderance was seen with a male to female ratio being 1:1.15 [Table 1]. Extremity was the most common site of primary tumor seen in 76% ($n = 32$) of all patients. Retroperitoneum (7%) and neck (7%) were the next common site of primary tumor [Table 2].

The most common site of metastasis was lung (69.7%) followed by lymph node and bone with the incidence being 18.6% and 11.6%, respectively. Liver metastasis was uncommon and present in only 6.9% of patients.

Thirteen patients did not receive any chemotherapy in view of poor PS. Thirty patients received chemotherapy with a combination of ifosfamide and doxorubicin.

As expected synovial sarcoma being chemoresponsive malignancy overall response rate (ORR) was 87%. One patient showed a complete response to the

chemotherapy. The median progression-free survival was 8 months [Table 3]. Second-line chemotherapy on progression was received by only 8 patients. The overall median overall survival was 18 months.

Discussion

Synovial sarcoma occurs most commonly in adolescent and young adults. It occurs most commonly in the soft tissues of the extremities, especially near large joints, but other sites such as head and neck, lung, heart, mediastinum, and abdominal wall sites also have been reported.^[10] Patients with synovial sarcoma have relatively high rates of response to chemotherapy. Ifosfamide-based chemotherapy has been associated with improved disease-specific survival

Table 1: Characteristics of metastatic synovial sarcoma patients

Characteristic	n (%)
Sex ($n=43$)	
Male	20 (46.5)
Female	23 (53.5)
Age (years)	
Median age	30
<18	5 (11.7)
18-60	37 (86.0)
>60	1 (2.3)
Histology	
Monophasic	28 (65.2)
Biphasic	13 (30.2)
No data	2 (4.6)
Pattern of metastasis	
Lung	38 (88.9)
Lymph node	3 (6.9)
Bone	2 (4.6)
Liver	2 (4.6)
Chemotherapy	
Received	30 (69.7)
Not received	13 (30.3)

Table 2: Site of primary tumor

Primary tumor	Number of patients (%)
Lower limb	25 (58.1)
Upper limb	8 (18.7)
Trunk	2 (4.6)
Chest wall	2 (4.6)
Retroperitoneum	3 (7.0)
Neck	3 (7.0)

Table 3: Response to chemotherapy

Response	n (%)
Complete response	1 (3.3)
Partial response	17 (56.7)
Stable disease	8 (26.7)
Progressive disease	4 (13.3)

with chemotherapy compared with no chemotherapy.^[11,12] Ifosfamide appears to be most active agent with ORR of around 30%–55%.^[13,14] We found that ORR with ifosfamide and doxorubicin 85% which is higher than as reported by Stefan Sleijfer *et al.*^[15] Patients with lung only metastasis had better survival 18 months and 12 months as shown in Figure 1. Similar observation reported by Salah *et al.*^[16]

Other newer drugs which showed some efficacy in metastatic synovial sarcoma are pazopanib and sunitinib.^[17,18] Pazopanib showed activity in a variety of STS including synovial sarcoma in various phase 2 and phase 3 clinical trials.^[19-21] Olaratumab is a recombinant human monoclonal antibody that specifically targets PDGFR α , blocking PDGF-AA, PDGF-BB, and PDGF-CC binding and receptor activation. The result of the phase 1b/2 study, randomizing 133 patients to receive olaratumab plus doxorubicin or doxorubicin alone, showed a median progression-free survival of 6.6 months and 4.1 months. Median survival was 26.5 months and 14.7 months in experimental versus doxorubicin arm.^[22]

Immunotherapy has been one of the major breakthroughs in oncology, for both solid and hematological tumors. In the SARC028 phase 2 study, pembrolizumab as a single agent showed activity in unselected STS of all types, with an ORR of 17.5%.^[23]

Conclusion

Metastatic synovial sarcoma is a chemoresponsive malignancy with good response to ifosfamide and doxorubicin. Patients with extrapulmonary metastasis have dismal prognosis. There is a need for better novel agents for achieving better treatment outcomes.

Financial support and sponsorship

Nil.




Figure 1: Survival curve comparing lung only metastasis versus other site of metastasis

Conflicts of interest

There are no conflicts of interest.

References

1. Corey RM, Swett K, Ward WG. Epidemiology and survivorship of soft tissue sarcomas in adults: A National Cancer Database report. *Cancer Med* 2014;3:1404-15.
2. Eilber FC, Dry SM. Diagnosis and management of synovial sarcoma. *J Surg Oncol* 2008;97:314-20.
3. Lewis JJ, Antonescu CR, Leung DH, Blumberg D, Healey JH, Woodruff JM, *et al.* Synovial sarcoma: A multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. *J Clin Oncol* 2000;18:2087-94.
4. Fisher C. Synovial sarcoma. *Ann Diagn Pathol* 1998;2:401-21.
5. Kadoch C, Crabtree GR. Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma. *Cell* 2013;153:71-85.
6. Hajdu SI, Shiu MH, Fortner JG. Tendosynovial sarcoma: A clinicopathological study of 136 cases. *Cancer* 1977;39:1201-17.
7. Cadman NL, Soule EH, Kelly PJ. Synovial sarcoma; an analysis of 34 tumors. *Cancer* 1965;18:613-27.
8. Palmerini E, Staals EL, Alberghini M, Zanella L, Ferrari C, Benassi MS, *et al.* Synovial sarcoma: Retrospective analysis of 250 patients treated at a single institution. *Cancer* 2009;115:2988-98.
9. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, *et al.* New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). *Eur J Cancer* 2009;45:228-47.
10. Rajeev LK, Patidar R, Babu G, Suresh Babu MC, Lokesh KN, Patil Okaly GV, *et al.* A rare case of primary synovial sarcoma of lung. *Lung India* 2017;34:545-7.
11. Jain A, Sajeewan KV, Babu KG, Lakshmaiah KC. Chemotherapy in adult soft tissue sarcoma. *Indian J Cancer* 2009;46:274-87.
12. Eilber FC, Brennan MF, Eilber FR, Eckardt JJ, Grobmyer SR, Riedel E, *et al.* Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. *Ann Surg* 2007;246:105-13.
13. Spurrell EL, Fisher C, Thomas JM, Judson IR. Prognostic factors in advanced synovial sarcoma: An analysis of 104 patients treated at the Royal Marsden hospital. *Ann Oncol* 2005;16:437-44.
14. Bokemeyer C, Franzke A, Hartmann JT, Schöber C, Arseniev L, Metzner B, *et al.* A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. *Cancer* 1997;80:1221-7.
15. Sleijfer S, Ouali M, van Glabbeke M, Krarup-Hansen A, Rodenhuis S, Le Cesne A, *et al.* Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: An exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). *Eur J Cancer* 2010;46:72-83.
16. Salah S, Yaser S, Salem A, Al Mousa A, Abu Sheikha A, Sultan I, *et al.* Factors influencing survival in metastatic synovial sarcoma: Importance of patterns of metastases and the first-line chemotherapy regimen. *Med Oncol* 2013;30:639.
17. Schöffski P. Pazopanib in the treatment of soft tissue sarcoma. *Expert Rev Anticancer Ther* 2012;12:711-23.
18. George S, Merriam P, Maki RG, Van den Abbeele AD, Yap JT,

- Akhurst T, *et al.* Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. *J Clin Oncol* 2009;27:3154-60.
19. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schöffski P, *et al.* Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: A phase II study from the European Organization for Research and Treatment of Cancer-soft tissue and bone sarcoma group (EORTC study 62043). *J Clin Oncol* 2009;27:3126-32.
 20. Deeks ED. Pazopanib: In advanced soft tissue sarcoma. *Drugs* 2012;72:2129-40.
 21. van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, *et al.* Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial. *Lancet* 2012;379:1879-86.
 22. Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, *et al.* Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: An open-label phase 1b and randomised phase 2 trial. *Lancet* 2016;388:488-97.
 23. Tawbi HA, Burgess MA, Crowley J, Van Tine BA, Hu J, Schuetz S, *et al.*, and for SARC028 Investigators. Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): Results of SARC028—A multicenter phase II study. *Journal of Clinical Oncology* 2016;34(Suppl 15);11006-11006. *ASCO Journals*.